190 related articles for article (PubMed ID: 27233282)
1. Production of Chikungunya Virus-Like Particles and Subunit Vaccines in Insect Cells.
Metz SW; Pijlman GP
Methods Mol Biol; 2016; 1426():297-309. PubMed ID: 27233282
[TBL] [Abstract][Full Text] [Related]
2. Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits.
Metz SW; Martina BE; van den Doel P; Geertsema C; Osterhaus AD; Vlak JM; Pijlman GP
Vaccine; 2013 Dec; 31(51):6092-6. PubMed ID: 24099875
[TBL] [Abstract][Full Text] [Related]
3. Effective chikungunya virus-like particle vaccine produced in insect cells.
Metz SW; Gardner J; Geertsema C; Le TT; Goh L; Vlak JM; Suhrbier A; Pijlman GP
PLoS Negl Trop Dis; 2013; 7(3):e2124. PubMed ID: 23516657
[TBL] [Abstract][Full Text] [Related]
4. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus.
Brandler S; Ruffié C; Combredet C; Brault JB; Najburg V; Prevost MC; Habel A; Tauber E; Desprès P; Tangy F
Vaccine; 2013 Aug; 31(36):3718-25. PubMed ID: 23742993
[TBL] [Abstract][Full Text] [Related]
5. Expression and Purification of E2 Glycoprotein from Insect Cells (Sf9) for Use in Serology.
Chua CL; Sam IC; Chan YF
Methods Mol Biol; 2016; 1426():51-61. PubMed ID: 27233260
[TBL] [Abstract][Full Text] [Related]
6. Alphavirus capsid proteins self-assemble into core-like particles in insect cells: A promising platform for nanoparticle vaccine development.
Hikke MC; Geertsema C; Wu V; Metz SW; van Lent JW; Vlak JM; Pijlman GP
Biotechnol J; 2016 Feb; 11(2):266-73. PubMed ID: 26287127
[TBL] [Abstract][Full Text] [Related]
7. Expression and evaluation of Chikungunya virus E1 and E2 envelope proteins for serodiagnosis of Chikungunya virus infection.
Cho B; Jeon BY; Kim J; Noh J; Kim J; Park M; Park S
Yonsei Med J; 2008 Oct; 49(5):828-35. PubMed ID: 18972604
[TBL] [Abstract][Full Text] [Related]
8. Using Bicistronic Baculovirus Expression Vector System to Screen the Compounds That Interfere with the Infection of Chikungunya Virus.
Kuo SC; Teng CY; Ho YJ; Chen YJ; Wu TY
Methods Mol Biol; 2016; 1426():263-72. PubMed ID: 27233279
[TBL] [Abstract][Full Text] [Related]
9. Recombinant Baculovirus: A Flexible Drug Screening Platform for Chikungunya Virus.
Varikkodan MM; Chen CC; Wu TY
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360656
[TBL] [Abstract][Full Text] [Related]
10. Functional processing and secretion of Chikungunya virus E1 and E2 glycoproteins in insect cells.
Metz SW; Geertsema C; Martina BE; Andrade P; Heldens JG; van Oers MM; Goldbach RW; Vlak JM; Pijlman GP
Virol J; 2011 Jul; 8():353. PubMed ID: 21762510
[TBL] [Abstract][Full Text] [Related]
11. Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus.
DeZure AD; Berkowitz NM; Graham BS; Ledgerwood JE
J Infect Dis; 2016 Dec; 214(suppl 5):S497-S499. PubMed ID: 27920180
[TBL] [Abstract][Full Text] [Related]
12. Comparative Efficacy of Mayaro Virus-Like Particle Vaccines Produced in Insect or Mammalian Cells.
Abbo SR; Nguyen W; Abma-Henkens MHC; van de Kamer D; Savelkoul NHA; Geertsema C; Le TTT; Tang B; Yan K; Dumenil T; van Oers MM; Suhrbier A; Pijlman GP
J Virol; 2023 Mar; 97(3):e0160122. PubMed ID: 36883812
[TBL] [Abstract][Full Text] [Related]
13. Development and evaluation of baculovirus-expressed Chikungunya virus E1 envelope proteins for serodiagnosis of Chikungunya infection.
Kumar P; Pok KY; Tan LK; Angela C; Leo YS; Ng LC
J Virol Methods; 2014 Sep; 206():67-75. PubMed ID: 24880071
[TBL] [Abstract][Full Text] [Related]
14. Bacteriophage Qβ virus-like particles displaying Chikungunya virus B-cell epitopes elicit high-titer E2 protein antibodies but fail to neutralize a Thailand strain of Chikungunya virus.
Basu R; Zhai L; Rosso B; Tumban E
Vaccine; 2020 Mar; 38(11):2542-2550. PubMed ID: 32044164
[TBL] [Abstract][Full Text] [Related]
15. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
[TBL] [Abstract][Full Text] [Related]
16. Antigenicity and immunogenicity of chikungunya virus-like particles from mosquito cells.
Tsai SK; Hsu YL; Chiao DJ; Shu PY; Lin HT; Chang SF; Lin HC; Huang SH; Wang CH; Hsiung CC; Lin CC; Wu TY; Kuo SC
Appl Microbiol Biotechnol; 2023 Jan; 107(1):219-232. PubMed ID: 36434113
[TBL] [Abstract][Full Text] [Related]
17. Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency.
Warter L; Lee CY; Thiagarajan R; Grandadam M; Lebecque S; Lin RT; Bertin-Maghit S; Ng LF; Abastado JP; Desprès P; Wang CI; Nardin A
J Immunol; 2011 Mar; 186(5):3258-64. PubMed ID: 21278338
[TBL] [Abstract][Full Text] [Related]
18. An in vitro refolding method to produce oligomers of anti-CHIKV, E2-IgM Fc fusion subunit vaccine candidates expressed in E. coli.
Kumar S; Singh VK; Vasam M; Patil PS; Dhaked RK; Ansari AS; Lohiya NK; Parashar D; Tapryal S
J Immunol Methods; 2020 Dec; 487():112869. PubMed ID: 32971119
[TBL] [Abstract][Full Text] [Related]
19. Dissecting the Role of E2 Protein Domains in Alphavirus Pathogenicity.
Weger-Lucarelli J; Aliota MT; Wlodarchak N; Kamlangdee A; Swanson R; Osorio JE
J Virol; 2015 Dec; 90(5):2418-33. PubMed ID: 26676771
[TBL] [Abstract][Full Text] [Related]
20. Production of Virus-Like Particles for Vaccination.
Thompson CM; Aucoin MG; Kamen AA
Methods Mol Biol; 2016; 1350():299-315. PubMed ID: 26820864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
